Verrica Pharmaceuticals (VRCA) Cash & Equivalents (2017 - 2026)

Verrica Pharmaceuticals' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $20.6 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 30.39% year-over-year to $20.6 million; the TTM figure through Mar 2026 stood at $20.6 million (down 30.39% YoY), while the FY2025 annual figure was $30.1 million, down 34.93% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $20.6 million, down from $30.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $84.3 million in Q3 2023, with the low at $15.4 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $34.3 million (2022), against an average of $41.1 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents soared 159.62% in 2023, then plunged 72.72% in 2024.
• Verrica Pharmaceuticals' Cash & Equivalents stood at $34.3 million in 2022, then soared by 102.92% to $69.5 million in 2023, then plunged by 33.38% to $46.3 million in 2024, then slumped by 34.93% to $30.1 million in 2025, then slumped by 31.67% to $20.6 million in 2026.
• Business Quant data shows VRCA's Cash & Equivalents at $20.6 million in Q1 2026, $30.1 million in Q4 2025, and $21.1 million in Q3 2025.